Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.0 million.

  • Marker Therapeutics' Profit After Tax rose 1341.01% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.3 million, marking a year-over-year decrease of 4841.5%. This contributed to the annual value of -$10.7 million for FY2024, which is 2359.82% up from last year.
  • As of Q3 2025, Marker Therapeutics' Profit After Tax stood at -$2.0 million, which was up 1341.01% from -$4.0 million recorded in Q2 2025.
  • Marker Therapeutics' Profit After Tax's 5-year high stood at -$2.0 million during Q3 2025, with a 5-year trough of -$9.9 million in Q1 2022.
  • Moreover, its 4-year median value for Profit After Tax was -$3.9 million (2022), whereas its average is -$4.4 million.
  • As far as peak fluctuations go, Marker Therapeutics' Profit After Tax skyrocketed by 5690.55% in 2023, and later tumbled by 8581.34% in 2025.
  • Quarter analysis of 4 years shows Marker Therapeutics' Profit After Tax stood at -$3.9 million in 2022, then rose by 28.95% to -$2.7 million in 2023, then crashed by 40.05% to -$3.8 million in 2024, then skyrocketed by 47.92% to -$2.0 million in 2025.
  • Its Profit After Tax was -$2.0 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$4.4 million in Q1 2025.